top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.010 +0.027 (+2.78%)
Streaming Delayed Price Updated: 11:07 AM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files for Rare Pediatric Disease Designation for Measles Drug Candidate
Via Investor Brand Network
News headline image
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Initiate Phase II MPox Trial in DRC
Via Investor Brand Network
Topics Intellectual Property
News headline image
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) to Present at NIBA Investment Conference As NV-387 Oral Gummies Drug Supply Completed
Via Investor Brand Network
News headline image
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox
Via Investor Brand Network
Topics Intellectual Property
News headline image
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
Via ACCESS Newswire
News headline image
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX)
Via AB Newswire
Topics Death
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 as Measles Treatment
Via Investor Brand Network
Topics Intellectual Property
News headline image
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres
Via ACCESS Newswire
News headline image
NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference
Via ACCESS Newswire
BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Need for Broad-Spectrum Antivirals Amid Severe Influenza Season
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2
Via ACCESS Newswire
News headline image
2 Small-Cap Biotechs That Could Reward Patient Investors ↗
Via MarketBeat
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Signs Master Services Agreement With Only Orphans Cote for NV-387 Orphan Drug Strategy
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Files Quarterly Report Highlighting Broad-Spectrum Antiviral Candidate NV-387
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
Via ACCESS Newswire
News headline image
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Closes $6 Million Registered Direct Offering With Concurrent Private Placement of Warrants
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces $6 Million Registered Direct Offering with Concurrent Private Placement of Warrants
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Receives Regulatory Approval to Begin Phase II Trial of NV-387 for Treatment of MPox in the DRC
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Date and Location of 2025 Annual Shareholders Meeting
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page